Business Context and Reporting Period
Pharmacyte Biotech, Inc. (PMCB) filed a Form 8-K on February 2, 2023, reporting events occurring on January 31, 2023. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure relates to capital allocation:
- New Share Repurchase Authorization: Up to $10 million.
- Existing Program Status: As of January 31, 2023, the company repurchased 3,410,624 shares for approximately $9.3 million under a program enacted in June 2022.
- Funding Source: The new program is expected to be funded with available cash.
Material Changes
The material change reported is the authorization of a new two-year share repurchase program effective immediately. This supplements the existing program, under which the company has already spent approximately $9.3 million.
Guidance, Outlook, and Risks
Management indicated that the timing, number of shares, and prices paid under the new program will depend on general business and market conditions, the trading price of the common stock, and regulatory limitations. The program does not obligate the company to acquire a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time.
Investor Verification Checklist
- Verify the company's current cash balance to assess the ability to fund the new $10 million repurchase program alongside the existing $9.3 million commitment.
- Review the press release (Exhibit 99.1) for any additional details on the rationale for the buyback.
- Monitor subsequent filings for actual repurchase activity and pricing under the new program.